Robert J. Israel

Learn More
PRO 542 (CD4-IgG2) is a recombinant antibody-like fusion protein wherein the Fv portions of both the heavy and light chains of human IgG2 have been replaced with the D1D2 domains of human CD4. Unlike monovalent and divalent CD4-based proteins, tetravalent PRO 542 potently neutralizes diverse primary human immunodeficiency virus (HIV) type 1 isolates. In(More)
Immunization with GMK vaccine (G M2 ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti-G M2 antibodies in close to 100% of patients. We found previously that anti-G D2 antibodies could be induced in some patients using G D2-keyhole limpet hemocyanin ؉ QS-21 (GDK). In this trial, we wished: (a) to determine whether(More)
BACKGROUND Subcutaneous methylnaltrexone (MNTX), dosed based on body weight, is efficacious and well tolerated in inducing bowel movements in patients with advanced illness and opioid-induced constipation (OIC); however, fixed-dose administration of MNTX may improve ease of administration. OBJECTIVE The study objective was to assess safety and efficacy of(More)
In a previous randomized Phase III trial (P. O. Livingston et al, J. Clin. Oncol., 12: 1036-1044, 1994), we demonstrated that immunization with GM2 and bacille Calmette-Guerin reduced the risk of relapse in stage III melanoma patients who were free of disease after surgical resection and who had no preexisting anti-GM2 antibodies. That vaccine formulation(More)
BACKGROUND Protease inhibitors such as ritonavir can cause nausea and vomiting which is the most common reason for discontinuation. Rats react to nauseous and emetic stimuli by increasing their oral intake of non-nutritive substances like kaolin, known as pica behavior. In this study, we evaluated the effects of methylnaltrexone, a peripherally acting(More)
R ifaximin is a nonsystemic antibiotic indicated for diarrhea-predominant irritable bowel syndrome (IBS-D) (1). A randomized, double-blind (DB), placebo-controlled, phase 3 trial (TARGET 3; NCT01543178) assessed up to three 2-week courses of rifaximin (2). Adults with IBS-D who responded to 2 weeks of open-label rifaximin treatment (550 mg three times a day(More)
OBJECTIVE This phase 2 study evaluated the safety and activity of intravenous methylnaltrexone on the duration of postoperative ileus in patients undergoing segmental colectomy. METHODS Adults (aged 18 years or older) with American Society of Anesthesiologists physical status of I, II, or III who underwent segmental colectomy, including partial colectomy,(More)
  • 1